Life expectancy after bariatric surgery or usual care in patients with or without baseline type 2 diabetes in Swedish Obese Subjects.

Autor: Carlsson LMS; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Carlsson B; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Jacobson P; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Karlsson C; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Andersson-Assarsson JC; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Kristensson FM; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Region Västra Götaland, Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden., Ahlin S; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Region Västra Götaland, Department of Clinical Physiology, NU Hospital Group, Trollhättan, Sweden., Svensson PA; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Taube M; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Näslund I; Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Karason K; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Peltonen M; Finnish Institute for Health and Welfare, Helsinki, Finland., Sjöholm K; Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. kajsa.sjoholm@medic.gu.se.
Jazyk: angličtina
Zdroj: International journal of obesity (2005) [Int J Obes (Lond)] 2023 Oct; Vol. 47 (10), pp. 931-938. Date of Electronic Publication: 2023 Jul 12.
DOI: 10.1038/s41366-023-01332-2
Abstrakt: Objectives: To determine life expectancy and causes of death after bariatric surgery in relation to baseline type 2 diabetes (T2D) in the prospective, Swedish Obese Subjects study.
Methods: The study included 2010 patients with obesity who underwent bariatric surgery and 2037 matched controls, eligible for surgery. The surgery group underwent gastric bypass (n = 265), banding (n = 376), or vertical banded gastroplasty (n = 1369). The control group (n = 2037) received usual obesity care. Causes of death were obtained from the Swedish Cause of Death Register, case sheets and autopsy reports, in patients with baseline T2D (n = 392 surgery patients/n = 305 controls) or non-T2D (n = 1609 surgery patients/n = 1726 controls) during a median follow-up 26 years.
Results: In T2D and non-T2D subgroups, bariatric surgery was associated with increased life expectancy (2.1, 95% confidence interval (95% CI) 0.2-4.0; and 1.6, 0.5-2.7 years, respectively) and reduced overall mortality (adjusted hazard ratio (adjHR) = 0.77, 95% CI: 0.61-0.97; and 0.82, 0.72-0.94, respectively), and the treatment benefit was similar (interaction p = 0.615). Bariatric surgery was associated with reduced cardiovascular mortality in both subgroups (adjHR = 0.65, 95% CI: 0.46-0.91; and 0.70, 0.55-0.88, respectively (interaction p = 0.516)).
Conclusions: Bariatric surgery is associated with similar reduction of overall and cardiovascular mortality and increased life expectancy regardless of baseline diabetes status.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: